UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 56

Sortiert nach

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

Leukemia, 2014-05, Vol.28 (5), p.1033-1040

2014

Volltextzugriff (PDF)

Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study

Journal of blood medicine, 2022-01, Vol.13, p.425-437

2022

Volltextzugriff (PDF)

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

Leukemia, 2015-12, Vol.29 (12), p.2452-2452

2015

Volltextzugriff (PDF)

Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome

Leukemia, 2013-04, Vol.27 (4), p.977-980

2013

Volltextzugriff (PDF)

Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia

Journal of clinical oncology, 2010-01, Vol.28 (3), p.437-444

2010

Volltextzugriff (PDF)

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

Haematologica (Roma), 2015-04, Vol.100 (4), p.479

2015

Volltextzugriff (PDF)

TARGETING RNA EPIGENETICS TO PREDICT AND OVERCOME DRUG RESISTANCE IN MDS AND AML

Leukemia research, 2023-05, Vol.128, p.107116, Article 107116

2023

Volltextzugriff (PDF)

First two cases of immune hemolytic anemia associated with ceftizoxime

Transfusion (Philadelphia, Pa.), 1999-08, Vol.39 (8), p.838-844

1999

Volltextzugriff (PDF)

Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions

Therapeutics and clinical risk management, 2016-01, Vol.12 (Issue 1), p.201-208

2016

Volltextzugriff (PDF)

Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

Leukemia, 2015-12, Vol.29 (12), p.2452-2452

2015

Volltextzugriff (PDF)

Etoposide and cytarabine as an effective and safe cytoreductive regimen for relapsed or refractory acute myeloid leukemia

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.6539-6539

2011

Volltextzugriff (PDF)

Randomized, dose-escalation study of the p38[alpha] MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome

Leukemia, 2013-04, Vol.27 (4), p.977

2013

Volltextzugriff (PDF)

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)

Journal of hematology and oncology, 2017-06, Vol.10 (1), p.131-131, Article 131

2017

Volltextzugriff (PDF)

An analysis of high ferritin levels before allogeneic hematopoietic cell transplantation (AlloHCT): A retrospective study to evaluate prognostic factors in patients (pts) undergoing AlloHCT for myelodysplasia

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.6562-6562

2011

Volltextzugriff (PDF)

Safety analysis of radioimmunotherapy (RIT) in patients with relapsed or refractory low grade, follicular or transformed non-Hodgkin's lymphoma and mantle cell lymphoma based on age at time of therapy

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e19529-e19529

2009

Volltextzugriff (PDF)

Use of a tumor-cell enrichment column for the enhanced detection of minimal residual disease in the BM or apheresis peripheral blood transplant products of breast-cancer patients

Cytotherapy (Oxford, England), 1999-01, Vol.1 (5), p.367-376

1999

Volltextzugriff (PDF)

A case report of sarcoma regression in a patient with MDS treated with lenalidomide

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.20535-20535

2007

Volltextzugriff (PDF)

Multicenter analysis of 81 solid organ transplant (SOT) recipients with posttransplantation lymphoproliferative disease (PTLD): Examination of survival and prognostic factors

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.8510-8510

2009

Volltextzugriff (PDF)

Immunoablation with high-dose cyclophosphamide for refractory multiple sclerosis

Multiple sclerosis, 2008-09, Vol.14, p.S181-S181

2008

Volltextzugriff (PDF)

Conditioning with Non-Targeted Busulfan and Fludarabine Followed by Allogeneic Stem Cell Transplantation: A Study of Engraftment Kinetics

Biology of blood and marrow transplantation, 2009-02, Vol.15 (2), p.112-112

2009

Volltextzugriff (PDF)

Assessing the impact of comorbidities on autologous hematopoietic cell transplant (AHCT) outcomes using the hematopoietic cell transplant-comorbidity index (HCT-CI) in lymphoma

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.7102-7102

2007

Volltextzugriff (PDF)

144: Autologous stem cell transplantation (ASCT) for patients with multiple myeloma (MM)

Biology of blood and marrow transplantation, 2007-02, Vol.13 (2), p.54-55

2007

Volltextzugriff (PDF)

54: Hematopoietic cell transplantation-comorbidity index (HCT-CI)

Biology of blood and marrow transplantation, 2007-02, Vol.13 (2), p.22-23

2007

Volltextzugriff (PDF)

Lamellar body number density and the prediction of respiratory distress

American journal of clinical pathology, 1991-06, Vol.95 (6), p.781-786

1991

Volltextzugriff (PDF)

The role of FDG-PET in low-grade non-Hodgkin lymphoma (NHL): Impact of histology

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.17534-17534

2006

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(54)

Publikationsform

Sprache

Englisch
(56)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(18)
Humans
(14)
Hematology
(11)
Female
(10)
Male
(8)
Middle Aged
(8)
Treatment Outcome
(8)
Aged
(7)
Oncology
(7)
Adult
(5)
Biological And Medical Sciences
(5)
Medical Sciences
(5)
Myelodysplastic Syndromes - Drug Therapy
(5)
Patients
(5)
Aged, 80 And Over
(4)
Anemia
(4)
Bone Marrow
(4)
Hematology, Oncology And Palliative Medicine
(4)
Leukemia
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome

Safety and Efficacy of Romiplostim in Patients With Lower-Risk Myelodysplastic Syndrome and Thrombocytopenia

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I

TARGETING RNA EPIGENETICS TO PREDICT AND OVERCOME DRUG RESISTANCE IN MDS AND AML

First two cases of immune hemolytic anemia associated with ceftizoxime

Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions

Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS

Etoposide and cytarabine as an effective and safe cytoreductive regimen for relapsed or refractory acute myeloid leukemia

Randomized, dose-escalation study of the p38[alpha] MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)

An analysis of high ferritin levels before allogeneic hematopoietic cell transplantation (AlloHCT): A retrospective study to evaluate prognostic factors in patients (pts) undergoing AlloHCT for myelodysplasia

Safety analysis of radioimmunotherapy (RIT) in patients with relapsed or refractory low grade, follicular or transformed non-Hodgkin's lymphoma and mantle cell lymphoma based on age at time of therapy

Use of a tumor-cell enrichment column for the enhanced detection of minimal residual disease in the BM or apheresis peripheral blood transplant products of breast-cancer patients

A case report of sarcoma regression in a patient with MDS treated with lenalidomide

Multicenter analysis of 81 solid organ transplant (SOT) recipients with posttransplantation lymphoproliferative disease (PTLD): Examination of survival and prognostic factors

Immunoablation with high-dose cyclophosphamide for refractory multiple sclerosis

Conditioning with Non-Targeted Busulfan and Fludarabine Followed by Allogeneic Stem Cell Transplantation: A Study of Engraftment Kinetics

Assessing the impact of comorbidities on autologous hematopoietic cell transplant (AHCT) outcomes using the hematopoietic cell transplant-comorbidity index (HCT-CI) in lymphoma

144: Autologous stem cell transplantation (ASCT) for patients with multiple myeloma (MM)

54: Hematopoietic cell transplantation-comorbidity index (HCT-CI)

Lamellar body number density and the prediction of respiratory distress

The role of FDG-PET in low-grade non-Hodgkin lymphoma (NHL): Impact of histology

Suchergebnisse filtern